Xenon Pharmaceuticals (NASDAQ:XENE) Rating Reiterated by Cantor Fitzgerald
Cantor Fitzgerald reissued their overweight rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report released on Tuesday, Benzinga reports. The firm currently has a $58.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts also recently issued research reports about the company. StockNews.com initiated coverage on Xenon Pharmaceuticals in […]